Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218
PRNewsWire
·
2026-04-28
·
via The Tech Buzz - Press Releases
SHANGHAI and NEW YORK, April 28, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies,
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。